Cridanimod

Cridanimod

SCHEMBL3801665

O=C(O)Cn1c2ccccc2c(=O)c2ccccc21.O=C(O)Cn1c2ccccc2c(=O)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 1.00
KDM4E B2RXH2 3/20 0.81
APEX1 P27695 1/20 0.63
P2RX4 Q99571 2/20 0.59
ALDH1A1 P00352 3/20 0.58
POLB P06746 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
MAPK1 P28482 1/20 0.55
STAT3 P40763 1/20 0.55
THRB P10828 1/20 0.55
MEN1 O00255 1/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
KMT2A Q03164 1/20 0.55
HSD17B10 Q99714 1/20 0.55
HPGD P15428 1/20 0.55
HTT P42858 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
RCE1 Q9Y256 1/20 0.55
FABP3 P05413 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cridanimod SCHEMBL3372087 1.00 GLA (1.00) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL29373385 1.00 GLA (1.00) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL27895128 0.98 GLA (0.96) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL3375823 0.98 GLA (0.96) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL3375819 0.98 GLA (0.96) GLAKDM4EAPEX1P2RX4ALDH1A1
SCHEMBL15732891 0.93 GLA (0.87) GLAKDM4EAPEX1P2RX4ALDH1A1
SCHEMBL29859932 0.90 KDM4E (1.00) GLAKDM4EAPEX1ALDH1A1POLB
SCHEMBL150053 0.90 KDM4E (1.00) GLAKDM4EAPEX1ALDH1A1POLB
SCHEMBL21027234 0.86 GLA (0.74) GLAKDM4EAPEX1P2RX4POLB
SCHEMBL21027012 0.86 GLA (0.74) GLAKDM4EAPEX1P2RX4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087399-A1 USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER SURKOV KIRILL GENNADIEVICH 2010-04-08 US disclosed
WO-2008121029-A2 USE OF 9-OXOACRIDINE-10-ACETIC ACID AND/OR SALTS AND/OR ITS ESTERS THEREOF FOR THE TREATMENT AND PROPHYLAXIS OF MALIGNANT TUMORS OF FEMALE REPRODUCTIVE SYSTEM SURKOV KIRILL GENNEDIEVICH (RU) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087399-A1 USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER ACR, APEH, CA9 GLA 1751/4885KDM4E 2986/4885APEX1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.